Sarepta Therapeutics Inc
Change company Symbol lookup
Select an option...
SRPT Sarepta Therapeutics Inc
WKCMF Wacker Chemie AG
SGB Southwest Georgia Financial Corp
BKRRF Blackrock Gold Corp
TGIOY Tung Ho Steel Enterprise Corp
AMLYY AMP Ltd
JBR Corporate Backed Trust Certificates
BSE BlackRock New York Municipal Income Quality Trust
GAPWP Georgia Power Co
FNBG FNB Bancorp
Go

Health Care : Biotechnology | Small Cap GrowthCompany profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Postmarket

Last Trade
Delayed
$36.55
-0.32 (-0.87%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$36.87
Day's Change
-0.56 (-1.50%)
Bid
--
Ask
--
B/A Size
--
Day's High
37.88
Day's Low
36.45
Volume
(Below Average)
Volume:
1,310,887
10-day average volume:
1,560,105
1,310,887
  • Prev Close
    37.43
  • Today's Open
    37.43
  • Day's Range
    36.45-37.88
  • Avg Vol (10-day)
    1.6M
  • Last (time)
    3:59p ET 08/17/17
  • Last (size)
    80
  • 52-Wk Range
    24.31 - 63.73
    LowHigh
  • (08/17/16 - 09/28/16)
    51.67%
  • 84.7%
  • Market Cap
    2.4B
  • Shares Outstanding
    64.3M
  • -2.44
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 1.0
  • 64.63
  • (% of float 07/31/17)
    18.70

Latest News

August 07, 2017
6:10 am ET
PR Newswire
July 31, 2017
6:30 pm ET
Globe Newswire
July 27, 2017
8:30 am ET
Globe Newswire
July 24, 2017
8:00 pm ET
Globe Newswire
7:00 am ET
Globe Newswire
July 19, 2017
5:37 pm ET
MarketWatch
4:01 pm ET
Globe Newswire
9:41 am ET
BusinessWire
8:30 am ET
Globe Newswire
July 18, 2017
4:35 pm ET
Globe Newswire
8:30 am ET
Globe Newswire
June 30, 2017
6:00 pm ET
Globe Newswire
June 28, 2017
4:01 pm ET
Globe Newswire
12:01 pm ET
PR Newswire
8:30 am ET
Globe Newswire
June 27, 2017
8:30 am ET
Globe Newswire
June 23, 2017
6:00 am ET
PR Newswire
June 21, 2017
1:30 pm ET
BusinessWire
7:00 am ET
Globe Newswire
May 31, 2017
6:30 pm ET
Globe Newswire
May 30, 2017
8:30 am ET
Globe Newswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2017 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by SunGard.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by , Computrade Systems, Inc.,, , , and

Copyright © 2017. All rights reserved.